Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors: A pediatric brain tumor consortium study

Cancer

Volumn 107, Issue 9, 2006, Pages 2291-2297

  Fouladi, Maryam ^a   Blaney, Susan M ^b   Poussaint, Tina Young ^c   Freeman III, Burgess B ^a   McLendon, Roger ^d   Fuller, Christine ^a   Adesina, Adekunle M ^b   Hancock, Michael L ^e   Danks, Mary K ^a   Stewart, Clinton ^a   Boyett, James M ^e   Gajjar, Amar ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e Operations and Biostatistics Center   (United States)

Author keywords

Oxaliplatin; Phase II trial; Recurrent medulloblastoma

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIEMETIC AGENT; ASPARTATE AMINOTRANSFERASE; GRANISETRON; ONDANSETRON; OXALIPLATIN; SEROTONIN ANTAGONIST;

ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLERGIC REACTION; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATYPICAL TERATOID RHABDOID TUMOR; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRAIN TUMOR; CANCER RESISTANCE; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; DEHYDRATION; DIARRHEA; DISEASE SEVERITY; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSESTHESIA; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; HEADACHE; HEPATOMEGALY; HUMAN; HYPONATREMIA; INFANT; INFECTION; LEUKOPENIA; LIVER TOXICITY; LYMPHOCYTOPENIA; MALE; MEDULLOBLASTOMA; NEPHROTOXICITY; NEUROECTODERM TUMOR; NEUROPATHIC PAIN; NEUTROPENIA; OTOTOXICITY; PARESTHESIA; PATIENT CODING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RHABDOID TUMOR; SEIZURE; SENSORY NEUROPATHY; SUPRATENTORIAL PRIMITIVE NEUROECTODERMAL TUMOR; THROMBOCYTOPENIA; TUMOR RECURRENCE; VOMITING;

ADOLESCENT; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; MEDULLOBLASTOMA; NEOPLASM RECURRENCE, LOCAL; NEUROECTODERMAL TUMORS, PRIMITIVE; ORGANOPLATINUM COMPOUNDS; RHABDOID TUMOR; SUPRATENTORIAL NEOPLASMS; TERATOMA; TREATMENT OUTCOME;

EID: 33750503089     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22241     Document Type: Article

References (44)

1. Bouffet E, Doz F, Demaille MC, et al. Improving survival in recurrent medulloblastoma: earlier detection, better treatment or still an impasse? Br J Cancer. 1998;77:1321-1326.
2. Ashley DM, Meier L, Kerby T, et al. Response of recurrent medulloblastoma to low-dose oral etoposide. J Clin Oncol. 1996;14:1922-1927.
3. Crafts DC, Levin VA, Edwards MS, et al. Chemotherapy of recurrent medulloblastoma with combined procarbazine, CCNU, and vincristine. J Neurosurg. 1978;49:589-592.
4. Lefkowitz IB, Packer RJ, Siegel KR, et al. Results of the treatment of children with recurrent medulloblastoma/primitive neuroectodermal tumors with lomustine and vincristine. Cancer. 1990;65:412-417.
5. Wara WM, Le QT, Sneed PK, et al. Pattern of recurrence of medulloblastoma after low-dose craniospinal radiotherapy. Int J Radiat Oncol Biol Phys. 1994;30:551-556.
6. Dunkel IJ, Boyett JM, Yates A, et al. High-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma. Children's Cancer Group. J Clin Oncol. 1998;16:222-228.
7. Sexauer CL, Khan A, Burger PC, et al. Cisplatin in recurrent pediatric brain tumors. A POG phase II study. A Pediatric Oncology Group Study. Cancer. 1985;56:1497-1501.
8. Walker RW, Allen JC. Cisplatin in the treatment of recurrent childhood primary brain tumors. J Clin Oncol. 1988;6:62-66.
9. Bertolone SJ, Baum ES, Krivit W, et al. A phase II study of cisplatin therapy in recurrent childhood brain tumors. A report from the Childrens Cancer Study Group. J Neurooncol. 1989;7:5-11.
10. Allen JC, Walker R, Luks E, et al. Carboplatin and recurrent childhood brain tumors. J Clin Oncol. 1987;5:459-463.
11. Gaynon PS, Ettinger LJ, Baum ES, et al. Carboplatin in childhood brain tumors. A Children's Cancer Study Group Phase II trial. Cancer. 1990;66:2465-2469.
12. Friedman HS, Krischer JP, Burger P, et al. Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: a Pediatric Oncology Group randomized phase II study. J Clin Oncol. 1992;10:249-256.
13. Packer RJ, Sutton LN, Elterman R, et al. Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. J Neurosurg. 1994;81:690-698.
14. Packer RJ, Goldwein J, Nicholson HS, et al. Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy. A Children's Cancer Group Study. J Clin Oncol 1999;17:2127-2136.
15. Strother D, Ashley D, Kellie SJ, et al. Feasibility of four consecutive high-dose chemotherapy cycles with stem-cell rescue for patients with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor after craniospinal radiotherapy: results of a collaborative study. J Clin Oncol 2001;19:2696-2704.
16. Knight KR, Kraemer DF, Neuwelt EA. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol. 2005;23:8588-8596.
17. Kraker AJ, Moore CW. Accumulation of cis-diamminedichloroplatinum(II) and platinum analogues by platinum-resistant murine leukemia cells in vitro. Cancer Res. 1988;48:9-13.
18. Pendyala L, Creaven PJ. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res. 1993;53:5970-5976.
19. Rixe O, Ortuzar W, Alvarez M, et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol. 1996;52:1855-1865.
20. Fukuda M, Ohe Y, Kanzawa F, et al. Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin. Anticancer Res. 1995;15:393-398.
21. Dunn TA, Schmoll HJ, GrunwaJd V, et al. Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines. Invest New Drugs. 1997;15:109-114.
22. Mamenta EL, Poma EE, Kaufmann WK, et al. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res. 1994;54:3500-3505.
23. Schmidt W, Chaney SG. Role of carrier ligand in platinum resistance of human carcinoma cell lines. Cancer Res. 1993;53:799-805.
24. Fink D, Nebel S, Aebi S, et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res. 1996;56:4881-4886.
25. Aebi S, Kurdi-Haidar B, Gordon R, et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res. 1996;56:3087-3090.
26. Vaisman A, Varchenko M, Umar A, et al. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res. 1998;58:3579-3585.
27. Fink D, Zheng H, Nebel S, et al. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res. 1997;57:1841-1845.
28. Strandberg MC, Bresnick E, Eastman A. The significance of DNA cross-linking to cis-diamminedichloroplatinum(II)-induced cytotoxicity in sensitive and resistant lines of murine leukemia L1210 cells. Chem Biol Interact. 1982;39:169-180.
29. Armand JP, Boige V, Raymond E, et al. Oxaliplatin in colorectal cancer: an overview. Semin Oncol. 2000;27:96-104.
30. Becouarn Y, Rougier P. Clinical efficacy of oxaliplatin monotherapy: phase II trials in advanced colorectal cancer. Semin Oncol. 1998;25:23-31.
31. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938-2947.
32. Raderer M, Wohrer S, Bartsch R, et al. Phase II study of oxaliplatin for treatment of patients with mucosa-associated lymphoid tissue lymphoma. J Clin Oncol. 2005;23:8442-8446.
33. Pratt CB, Spunt SL, Thompson SJ. Phase I study of oxaliplatin in pediatric patients with malignant solid tumors [Abstract]. Proc Am Soc Clin Oncol. 2001;1498.
34. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1-10.
35. Casella G. Refining binomial confidence intervals. Can J Stat. 1987;14:113-129.
36. Morrison JG, White P, McDougall S, et al. Validation of a highly sensitive ICP-MS method for the determination of platinum in biofluids: application to clinical pharmacokinetic studies with oxaliplatin. J Pharm Biomed Anal. 2000;24:1-10.
37. NONMEM Project Group. NONMEM Users' Guide. University of California at San Francisco, 1992.
38. Iacono LC, Spunt S, Pratt CB, et al. Pharmacokinetics of oxaliplatin in children with solid tumors [Abstract]. Proc Am Soc Clin Oncol. 2002;21.
39. Brandt JR, Wong C, Jones DR, et al. Glomerular filtration rate in children with solid tumors: normative values and a new method for estimation. Pediatr Hematol Oncol. 2003;20:309-318.
40. Torres CF, Rebsamen S, Silber JH, et al. Surveillance scanning of children with medulloblastoma. N Engl J Med. 1994;330:892-895.
41. Graham MA, Lockwood GF, Greenslade D, et al. Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res. 2000;6:1205-1218.
42. Delord JP, Umlil A, Guimbaud R, et al. Population pharmacokinetics of oxaliplatin. Cancer Chemother Pharmacol. 2003;51:127-131.
43. Bastian G, Barrail A, Urien S. Population pharmacokinetics of oxaliplatin in patients with metastatic cancer. Anticancer Drugs. 2003;14:817-824.
44. Massari C, Brienza S, Rotarski M, et al. Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function. Cancer Chemother Pharmacol. 2000;45:157-164.